The ‘business DNA’ of the bioscience sector is mutating. Who will win this Darwinian race, and how will open innovation support them? Like other sectors, bioscience is facing a transformation in the coming years through the increased use of open innovation and collaboration. The business imperative is as clear as the scientific advantage: new opportunities and new solutions arising from the collective intelligence of peers, collaborators and ‘the unusual suspects’. The winners will be those who understand the need to join in. Join the conversation with sector leaders and innovators. Our keynote speaker is Ian Tomlinson, Senior Vice President, GlaxoSmithKline.
The synergistic combination of two or more distinct technologies creating a new hybrid device, process or product applied in health prevention, screening, diagnosis, therapy, monitoring or functional enhancement.
Stevenage Bioscience Catalyst's Convergent Medical Technologies is a full day conference for the bioscience sector, focused on making cutting-edge new products a reality. Facilitated by key opinion leaders across technological areas, this day of interactive sessions is a must for anyone interested in drugs, devices, diagnostics, ICT, nanotechnology, regenerative medicine, e-health, robotics, biosensors....
Open Innovation in Action saw 160 people converge at the UK’s first open innovation bioscience campus, Stevenage Bioscience Catalyst (SBC). Business leaders from the biotech sector, big pharma, investors, academics, clinicians and entrepreneurs explored theopportunities that Open Innovation has to offer the bioscience sector. Delegates included GlaxoSmithKline, GE LifeSciences, Unilever, Philips Research, Innocentive, Caprion Proteomics, TheWellcome Trust, MRC, and Cambridge Enterprise.
Highlights included keynotes from Patrick Vallance, President of Pharmaceuticals R&D at GlaxoSmithKline, and Stefan Lindegaard, open innovation expert and author; a robust expert panel discussion on the highs and lows of open innovation; and a total of eight lively and informative breakout sessions on topics including crowd-funding for the biotech sector, intellectual property, and free access to the research literature.